Perivinc Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 30-12-2024
- Paid Up Capital ₹ 3.94 Cr
as on 30-12-2024
- Company Age 14 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 Cr
as on 30-12-2024
- Satisfied Charges ₹ 7.00 Cr
as on 30-12-2024
- Revenue 49.67%
(FY 2021)
- Profit 510.84%
(FY 2021)
- Ebitda 19.19%
(FY 2021)
- Net Worth 14.04%
(FY 2021)
- Total Assets 7.46%
(FY 2021)
About Perivinc Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 3.94 Cr.
The company currently has active open charges totaling ₹2.00 Cr. The company has closed loans amounting to ₹7.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Patel Sankabhai, Sanjay Patel, Vaishali Totare, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230GJ2010PTC062038
- Company No.
062038
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Aug 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Perivinc Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Patel Sankabhai  | Director | 16-Apr-2019 | Current |
| Sanjay Patel | Director | 16-Apr-2019 | Current |
| Vaishali Totare | Director | 06-Mar-2018 | Current |
| Sanjay Totare | Director | 06-Mar-2018 | Current |
Financial Performance of Perivinc Pharmaceuticals.
Perivinc Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 49.67% increase. The company also saw a substantial improvement in profitability, with a 510.84% increase in profit. The company's net worth Soared by an impressive increase of 14.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Perivinc Pharmaceuticals?
In 2021, Perivinc Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Yashica Pharmaceuticals Private LimitedActive 17 years 1 monthVaishali Totare and Sanjay Totare are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 01 Feb 2023 | ₹2.00 Cr | Open |
Bank Of India Creation Date: 18 May 2013 | ₹3.50 Cr | Satisfied |
Bank Of India Creation Date: 11 May 2013 | ₹3.50 Cr | Satisfied |
How Many Employees Work at Perivinc Pharmaceuticals?
Unlock and access historical data on people associated with Perivinc Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Perivinc Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Perivinc Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
